URL Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
URL Pharma, Inc. - overview
Location
Philadelphia, PA, US
Primary Industry
Pharmaceuticals
About
URL Pharma, Inc. is a pharmaceutical company that specializes in the development and commercialization of prescription medications to treat various health conditions, ensuring effective therapeutic outcomes for patients. URL Pharma, Inc. is focused on creating and marketing pharmaceutical products, with a notable acquisition by Takeda Pharmaceutical Company Limited in April 2012 for USD 800 mn.
The company is headquartered in Philadelphia, US, and has expanded its operations internationally to cater to healthcare professionals. The firm has completed two deals, positioning itself strategically in the pharmaceutical market. URL Pharma specializes in developing and commercializing a range of pharmaceutical products, including branded medications like Zanaflex (tizanidine) for muscle relaxation, Benemid (probenecid) for chronic gout treatment, Clozaril for schizophrenia, and Lozol (indapamide) for hypertension. These offerings aim to provide effective therapeutic solutions in outpatient settings and are marketed across North America, Europe, and select regions in Asia, ensuring access for various healthcare providers.
URL Pharma's revenue is generated from direct sales of prescription medications to healthcare providers, hospitals, and pharmacies. The pricing of flagship products is competitive, with Zanaflex, Clozaril, and Benemid being key offerings that address ongoing health management needs. Sales transactions occur through direct engagement with healthcare professionals and partnerships with pharmaceutical distributors, allowing products to reach the end-users effectively. Following the acquisition by Takeda Pharmaceutical in April 2012, URL Pharma plans to leverage this partnership for future growth initiatives.
The company is expected to focus on developing new pharmaceutical products and expanding its reach into additional global markets, with specific emphasis on enhanced distribution in Europe and Asia by 2025. The funding from the acquisition will support these efforts, fostering innovations and strengthening its product portfolio.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.urlpharma.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
URL Pharma, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | URL Pharma, Inc. | - | ||||||||
| Growth | Completed | URL Pharma, Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.